U.S. markets open in 3 hours 59 minutes
  • S&P Futures

    3,757.25
    +0.50 (+0.01%)
     
  • Dow Futures

    30,028.00
    +46.00 (+0.15%)
     
  • Nasdaq Futures

    11,515.75
    -26.00 (-0.23%)
     
  • Russell 2000 Futures

    1,761.90
    +3.80 (+0.22%)
     
  • Crude Oil

    88.94
    +0.49 (+0.55%)
     
  • Gold

    1,721.70
    +0.90 (+0.05%)
     
  • Silver

    20.84
    +0.18 (+0.90%)
     
  • EUR/USD

    0.9811
    +0.0015 (+0.16%)
     
  • 10-Yr Bond

    3.8260
    0.0000 (0.00%)
     
  • Vix

    30.34
    +1.79 (+6.27%)
     
  • GBP/USD

    1.1208
    +0.0039 (+0.35%)
     
  • USD/JPY

    144.8390
    -0.2290 (-0.16%)
     
  • BTC-USD

    19,991.53
    -171.44 (-0.85%)
     
  • CMC Crypto 200

    455.23
    -7.90 (-1.71%)
     
  • FTSE 100

    7,005.63
    +8.36 (+0.12%)
     
  • Nikkei 225

    27,116.11
    -195.19 (-0.71%)
     

Carlisle (CSL) Stock Moves -1.65%: What You Should Know

·3 min read

Carlisle (CSL) closed the most recent trading day at $284.81, moving -1.65% from the previous trading session. This change was narrower than the S&P 500's daily loss of 1.71%. Meanwhile, the Dow lost 1.7%, and the Nasdaq, a tech-heavy index, lost 0.09%.

Prior to today's trading, shares of the diversified manufacturer had lost 5.82% over the past month. This has was narrower than the Conglomerates sector's loss of 11.17% and the S&P 500's loss of 8.68% in that time.

Wall Street will be looking for positivity from Carlisle as it approaches its next earnings report date. The company is expected to report EPS of $5.39, up 80.27% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.77 billion, up 34.65% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of $20.24 per share and revenue of $6.7 billion, which would represent changes of +114.41% and +36.83%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for Carlisle. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.12% higher. Carlisle is currently a Zacks Rank #1 (Strong Buy).

Valuation is also important, so investors should note that Carlisle has a Forward P/E ratio of 14.31 right now. For comparison, its industry has an average Forward P/E of 15.03, which means Carlisle is trading at a discount to the group.

Meanwhile, CSL's PEG ratio is currently 0.84. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Diversified Operations stocks are, on average, holding a PEG ratio of 1.62 based on yesterday's closing prices.

The Diversified Operations industry is part of the Conglomerates sector. This group has a Zacks Industry Rank of 64, putting it in the top 26% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow CSL in the coming trading sessions, be sure to utilize Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Carlisle Companies Incorporated (CSL) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research